AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37147301
Drug: Midostaurin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin added to intensive chemotherapy in late group (2016-2020)
Trial: 37147642
Drug: Oral dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dronabinol (BX-1) once daily before bedtime for 10 weeks
Trial: 37147642
Drug: Oral dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dronabinol (BX-1)
Trial: 37147667
Drug: Integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive behavioral treatment (ICBT)
Trial: 37147708
Drug: Depression (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants using illicit drugs in the last month
Trial: 37147725
Drug: Rapid outreach
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid outreach following missed doses as detected by an electronic adherence monitoring device
Trial: 37147725
Drug: Weekly check-in
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly check-in texts
Trial: 37147725
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of adherence monitoring and support components
Trial: 37147739
Drug: Home-based transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based transcranial direct current stimulation (tDCS) administered by caregivers under remote supervision.
Trial: 37148183
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure therapy (PAP)
Trial: 37148183
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia plus positive airway pressure (CBT-I+PAP)
Trial: 37148249
Drug: Litifilimab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Litifilimab (monoclonal antibody against BDCA2)
Trial: 37148266
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + 0.12% chlorhexidine gluconate mouthrinse twice a day for 3 mo + rubber interproximal bristle cleaners twice a day for 6 mo
Trial: 37148266
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + oral hygiene instructions (Control)
Trial: 37148266
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + 0.12% chlorhexidine gluconate mouthrinse twice a day for 3 mo + rubber interproximal bristle cleaners twice a day for 6 mo (in subjects with diabetes)
Trial: 37148831
Drug: Heated high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated high-flow nasal cannula (HFNC) therapy
Trial: 39374601
Drug: Once-weekly insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly insulin icodec
Trial: 39270686
Drug: Once-daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily insulin degludec
Trial: 37149257
Drug: Rehabilitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation group (exercise-based rehabilitation program consisting of two weekly sessions of physical exercise for 8 weeks and one educational session)
Trial: 37149701
Drug: Low-dose tamoxifen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tamoxifen (2.5, 5 mg)
Trial: 37149701
Drug: High-dose tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tamoxifen (10, 20 mg)
Trial: 37149701
Drug: Tamoxifen (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (any dose)
Trial: 37150144
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals (DAAs) treatment
Trial: 37150147
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to gliadin (AGA IgG)
Trial: 37150258
Drug: Fractionated brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated brain radiation therapy (RT)
Trial: 37150411
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake
Trial: 37150895
Drug: Extended-release melatonin
RxNorm normalized name: melatonin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release melatonin (4 mg)
Trial: 37150895
Drug: Immediate-release melatonin
RxNorm normalized name: melatonin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release melatonin (4 mg)
Trial: 37150952
Drug: Deucravacitinib (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib (once-daily oral pill)
Trial: 37150952
Drug: Placebo (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive pill)
Trial: 37150952
Drug: Apremilast (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast (twice-daily oral pill)
Trial: 37151105
Drug: 12-month testosterone
RxNorm normalized name: testosterone 12.5 MG/ACTUAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month testosterone replacement therapy (TRT)
Trial: 37151571
Drug: Mindfulness meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness meditation and auricular acupuncture (CIH therapies)
Trial: 37151894
Drug: Urine kidney
RxNorm normalized name: URINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine kidney injury molecule 1 (uKIM-1)
Trial: 37152360
Drug: vixotrigine 200
RxNorm normalized name: Vixotrigine
DrugBank: Vixotrigine (DB11706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vixotrigine 200 mg BID
Trial: 37152360
Drug: vixotrigine 350
RxNorm normalized name: Vixotrigine
DrugBank: Vixotrigine (DB11706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vixotrigine 350 mg BID
Trial: 37152361
Drug: INTEP-AR model
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INTEP-AR model (large Infarct, NIHSS score, Thrombolysis, Endovascular treatment, Pneumonia, brain Atrophy, and Recanalisation)
Trial: 37152367
Drug: Saline irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline irrigation (100 ml saline pulse irrigation after cholangiography)
Trial: 37153087
Drug: Bee venom
RxNorm normalized name: Bee venom
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bee venom (BV) phonophoresis with conservative treatment of medical ulcer care
Trial: 37153087
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment of medical ulcer care with ultrasound sessions only (control)
Trial: 37153587
Drug: serplulimab 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: serplulimab 4.5 mg/kg plus nab-paclitaxel 260 mg/m² for up to 2 years (35 dosing cycles)
Trial: 37153702
Drug: Intranasal OXT
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal OXT (Syntocinon, 40 USP units/mL, 4 IU/spray, 16 to 24 IU 3 times daily at mealtimes)
Trial: 37153770
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined olanzapine and sertraline
Trial: 37154020
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral rivaroxaban daily for 35 days
Trial: 37154608
Drug: Stromal Cells,
RxNorm normalized name: ALLOGENEIC-UNRELATED PLACENTA-DERIVED STROMAL CELLS, EXPANDED EX VIVO
DrugBank: Cenplacel-L (DB19188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stromal Cells, details on dosage and duration not available
Trial: 37155164
Drug: Pharmacogenetics-informed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetics-informed treatment (PIT) with TCAs (nortriptyline, clomipramine, or imipramine) based on CYP2D6 and CYP2C19 genotypes.
Trial: 37155164
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment with standard initial TCA dosage.
Trial: 37155164
Drug: Pharmacogenetics-informed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetics-informed treatment (PIT)
Trial: 37155171
Drug: Intravenous Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Ketamine plus Digital Training
Trial: 37155168
Drug: Whole-body hypothermia
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body hypothermia (reduction of rectal temperatures to between 33.0 °C and 34.0 °C for 72 hours)
Trial: 37155168
Drug: Control (rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (rectal temperatures maintained between 36.0 °C and 37.0 °C)
Trial: 39711430
Drug: Anlotinib plus
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib plus PD-1 inhibitor
Trial: 37156249
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus IBI305 plus chemotherapy (pemetrexed and cisplatin)
Trial: 37156249
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus IBI305 plus chemotherapy
Trial: 39374601
Drug: Once-daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily insulin glargine U100
Trial: 37156466
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg (up to 100 mg)
Trial: 37156466
Drug: Weight categories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight categories (≤90 kg: 40 mg; 91-130 kg: 60 mg; 131-170 kg: 80 mg; >170 kg: 100 mg)
Trial: 37156551
Drug: Transgenic adoptive
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transgenic adoptive cell therapy (ACT) with NY-ESO-1-specific TCR transgenic lymphocytes, NY-ESO-1 peptide-pulsed dendritic cell (DC) vaccination, and nivolumab-mediated PD-1 blockade
Trial: 37156588
Drug: Shortened antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened antibiotic treatment of 5 days
Trial: 37156588
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment of 7 days or longer
Trial: 37158010
Drug: Vaccine willingness
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine willingness
Trial: 37158083
Drug: Lipid-lowering therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy, details not available
Trial: 37158780
Drug: Virtual 'Coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual 'Coping with Brain Fog' intervention, details on dosage and duration not available
Trial: 37158831
Drug: Rifapentine 10
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 10 mg/kg for 17 or 26 weeks
Trial: 37158831
Drug: Rifapentine 15
RxNorm normalized name: rifapentine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine 15 mg/kg for 17 or 26 weeks
Trial: 37158831
Drug: Rifapentine 20
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 20 mg/kg for 17 or 26 weeks
Trial: 37158831
Drug: Standardized six-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized six-month treatment regimen (rifampicin, isoniazid, pyrazinamide, ethambutol for 26 weeks)
Trial: 37158911
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray plus an oral antidepressant (ESK + AD)
Trial: 37158911
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray plus an oral antidepressant (AD + PBO)
Trial: 37158925
Drug: Probiotics treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics treatment for 12 weeks
Trial: 37158965
Drug: Site-specific HCV
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Site-specific HCV treatment workflows utilizing direct-acting antivirals (DAAs) and a simplified treatment algorithm.
Trial: 37158965
Drug: Training of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training of providers on the use of a simplified HCV treatment algorithm with DAAs.
Trial: 37159195
Drug: Lactulose ingestion
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose ingestion (20 g) during a continuous 10-hour sodium d3-acetate intravenous infusion
Trial: 37159251
Drug: Red Bull
RxNorm normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Bull energy drink (250 mL administered 2 hours postoperatively and for breakfast and lunch on postoperative day 1, totaling 750 mL per 24 hours)
Trial: 37159251
Drug: Still water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Still water (250 mL administered 2 hours postoperatively and for breakfast and lunch on postoperative day 1, totaling 750 mL per 24 hours)
Trial: 37159264
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside (NR) 1,000 mg/day
Trial: 37159264
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ10) 1,200 mg/day
Trial: 37160281
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (1.8 × 10^6 or 2.7 × 10^6 doses administered via direct venous inoculation at 8-week intervals)
Trial: 37160396
Drug: Ride-on-toy navigation
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ride-on-toy navigation training (RNT) programme, provided 4-5 times/week for 30-45 min/session over 6 weeks, in addition to conventional therapy.
Trial: 37160396
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy alone during the 6-week control phase.
Trial: 37160822
Drug: Pharmacologic strategies
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic strategies (acetaminophen and ibuprofen)
Trial: 37161345
Drug: Self-administered computerized
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered computerized mental health screening tool
Trial: 37161377
Drug: Single-dose MR-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose MR-guided partial breast irradiation (PBI) with a prescribed dose of 20 Gy to the tumor and 15 Gy to the surrounding breast tissue.
Trial: 37161377
Drug: Single-dose MR-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose MR-guided partial breast irradiation (PBI)
Trial: 37161571
Drug: Bedaquiline (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedaquiline (400-800 mg) and Rifampicin (150-600 mg)
Trial: 37161571
Drug: Rifampicin (150-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (150-600 mg)
Trial: 37161823
Drug: High-Intensity Lipid-Lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Lipid-Lowering Therapies
Trial: 37162000
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application designed to support patients with insulin therapy
Trial: 37162147
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of plecanatide
Trial: 37162147
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of plecanatide
Trial: 37162349
Drug: Model-based simulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-based simulations of various infusion modes
Trial: 37162744
Drug: Tildrakizumab 200
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tildrakizumab 200 mg every 4 weeks until week 24
Trial: 37163360
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + Radiotherapy (RT)
Trial: 37163622
Drug: Epicutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicutaneous immunotherapy delivered by means of a peanut patch for 12 months
Trial: 37163622
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered daily for 12 months
Trial: 37163622
Drug: Epicutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicutaneous immunotherapy delivered by means of a peanut patch
Trial: 37163623
Drug: Cabozantinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (40 mg daily) plus nivolumab (3 mg/kg) and ipilimumab (1 mg/kg)
Trial: 37163623
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg) and ipilimumab (1 mg/kg)
Trial: 37164012
Drug: BNT162b4 (mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b4 (mRNA vaccine targeting conserved non-spike antigens)
Trial: 37164012
Drug: BNT162b2 (spike-protein-encoding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (spike-protein-encoding vaccine)
Trial: 37164457
Drug: Monthly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly follow-up by a community-based stroke coordinator who identifies individual risk profiles and sets up action plans based on individual goals.
Trial: 37164457
Drug: Monthly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly follow-up by a community-based stroke coordinator.
Trial: 37164467
Drug: Low iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low iodine (20 µg/day) multivitamin and mineral supplement
Trial: 37164467
Drug: Identical supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical supplement containing 200 µg/day
Trial: 37164472
Drug: GBDPs group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBDPs group (treatment group)
Trial: 37164838
Drug: Inclisiran 100
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 100 mg
Trial: 37164838
Drug: Inclisiran 300
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 300 mg
Trial: 37164957
Drug: Ansofaxine 80
RxNorm normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ansofaxine 80 mg/day
Trial: 37164957
Drug: Ansofaxine 160
RxNorm normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ansofaxine 160 mg/day
Trial: 37165711
Drug: Gradual weaning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual weaning of EVD treatment (multi-step increase of resistance over days)
Trial: 37165711
Drug: Prompt closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt closure of EVD treatment
Trial: 37165711
Drug: Gradual weaning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual weaning of EVD treatment
Trial: 37165840
Drug: Zinpentraxin alfa
RxNorm normalized name: Zinpentraxin alfa
DrugBank: Zinpentraxin alfa (DB14852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinpentraxin alfa (RO7490677, PRM-151) administered intravenously weekly (QW) or every 4 weeks (Q4W)
Trial: 37165930
Drug: TNX-102 SL
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX-102 SL 2.8 mg for 2 weeks, followed by 5.6 mg for 12 weeks
Trial: 37166022
Drug: Short-term steroids
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term steroids
Trial: 37166053
Drug: PEP503 (NBTXR3)
RxNorm normalized name: Hafnium oxide-containing nanoparticles nbtxr3
DrugBank: Hafnium oxide (DB17508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP503 (NBTXR3) nanoparticles with radiotherapy and concurrent chemotherapy
Trial: 37166053
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (preoperative concurrent chemoradiotherapy)